Thiamine Hydrochloride

FRIDAY, Aug. 30, 2024 -- More than half of people around the world aren’t getting enough micronutrients essential to human health, including calcium, iron and vitamins C and E, a new study says. These deficiencies are contributing to global malnutrition, as well as health problems like blindness, increased vulnerability to infections, and pregnancy complications, researchers said in The Lancet Global Health . “These results are alarming,” researcher Ty Beal , a senior technical specialist at the Global Alliance for Improved Nutrition, said in a news release. “Most people — even more than previously thought, across all regions and countries of all incomes — are not consuming enough of multiple essential micronutrients,” Beal said. “These gaps compromise health outcomes and limit human potential on a global scale.” For the study, researchers combined data from several sources to compare the nutritional intake of people in 185 countries. The team specifically assessed intake of 15 vitamins and minerals -- calcium, iodine, iron, riboflavin, folate, zinc, magnesium, selenium, thiamin, niacin, and vitamins A, B6 , B12, C and E. Researchers found widespread inadequate intake of iodine (68% of the world's population); vitamin E (67%); calcium (66%); and iron (65%). More than half of people consume inadequate levels of riboflavin, folate, and vitamins C and B6, researchers added. Intake of niacin was closest to sufficient, with 22% of people worldwide consuming too little, followed by thiamin (30%) and selenium (37%). “The public health challenge facing us is immense, but practitioners and policymakers have the opportunity to identify the most effective dietary interventions and target them to the populations most in need,” senior author Christopher Golden , associate professor of nutrition and planetary health at the Harvard T.H. Chan School of Public Health, said in a news release. Women were more likely than men to get too little iodine, vitamin B12, iron and selenium, results indicate. On the other hand, men weren't getting enough niacin, thiamin, zinc, magnesium, and vitamins A, C, and B6 compared to women, researchers said. Children and young adults 10 to 30 were most prone to low calcium intake, especially in South and East Asia and sub-Saharan Africa. Calcium intake was also low across North America, Europe and Central Asia. “Our study is a big step forward,” co-lead author Chris Free , a research professor at the University of California-Santa Barbara, said in a news release. “Not only because it is the first to estimate inadequate micronutrient intakes for 34 age-sex groups in nearly every country, but also because it makes these methods and results easily accessible to researchers and practitioners.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

A study has revealed a link between gut microbiota and Parkinson's disease. The researchers discovered a decrease in bacterial genes related to the synthesis of vitamins B2 and B7. The lack of these genes was associated with reduced intestinal short-chain fatty acids and polyamines, agents that maintain the intestinal barrier and prevent the leakage of toxins into the blood that can then access the brain. Using B vitamin therapy to address these deficiencies may restore the barrier and treat Parkinson's disease. A study led by Nagoya University Graduate School of Medicine in Japan has revealed a link between gut microbiota and Parkinson's disease (PD). The researchers found a reduction in the gut bacteria of genes responsible for synthesizing the essential B vitamins B2 and B7. They also identified a relationship between the lack of these genes and low levels of agents that help maintain the integrity of the intestinal barrier. This barrier prevents toxins from entering the bloodstream, which causes the inflammation seen in PD. Their findings, published in npj Parkinson's Disease, suggest that treatment with B vitamins to address these deficiencies can be used to treat PD. PD is characterized by a variety of physical symptoms that hinder daily activities and mobility, such as shaking, slow movement, stiffness, and balance problems. While the frequency of PD may vary between different populations, it is estimated to affect approximately 1-2% of individuals aged 55 years or older. Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota. In ideal conditions, gut microbiota produce SCFAs and polyamines, which maintain the intestinal barrier that prevents toxins entering the bloodstream. Toxins in the blood can be carried to the brain where they cause inflammation and affect neurotransmission processes that are critical for maintaining mental health. To better understand the relationship between the microbial characteristics of the gut in PD, Hiroshi Nishiwaki and Jun Ueyama from the Nagoya University Graduate School of Medicine conducted a metanalysis of stool samples from patients with PD from Japan, the United States, Germany, China, and Taiwan. They used shotgun sequencing, a technique that sequences all genetic material in a sample. This is an invaluable tool because it offers researchers a better understanding of the microbial community and genetic makeup of the sample. They observed a decrease in the bacterial genes responsible for the synthesizing of riboflavin (vitamin B2) and biotin (vitamin B7) in patients diagnosed with PD. Riboflavin and biotin, derived from both food and gut microbiota, have anti-inflammatory properties, which may counteract the neuroinflammation seen in diseases like PD. B vitamins play crucial roles in the metabolic processes that influence the production and functions of short-chain fatty acids (SCFAs) and polyamines, two agents that help maintain the integrity of the intestinal barrier, preventing toxins entering the bloodstream. An examination of fecal metabolites revealed decreases of both in patients with PD. The findings indicate a potential explanation for the progression of PD. "Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in PD," Nishiwaki explained. "This higher permeability exposes nerves to toxins, contributing to abnormal aggregation of alpha-synuclein, activating the immune cells in the brain, and leading to long-term inflammation." He added, "Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue for alleviating PD symptoms and slowing disease progression." The results of the study highlight the importance of understanding the complex relationship among gut microbiota, metabolic pathways, and neurodegeneration. In the coming years, therapy could potentially be customized based on the unique microbiome pro each patient. By altering bacterial levels in the microbiome, doctors can potentially delay the onset of symptoms associated with diseases like PD. "We could perform gut microbiota analysis on patients or conduct fecal metabolite analysis," Nishiwaki said. "Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with decreased levels, potentially creating an effective treatment."